AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2013
Jan 3, 2013
30591_dirs_2013-01-03_1874266d-b705-43a9-ad8c-5985a81e0f2a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2013-01-02
Reporting Person: HOUGEN ELIZABETH L (SVP, Finance and CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-01-02 | Employee Stock Option (right to buy) | $10.82 | A | 7500 | Acquired | 2020-01-01 | Common Stock (7500) | Direct |
| 2013-01-02 | Employee Stock Option (right to buy) | $10.82 | A | 15700 | Acquired | 2020-01-01 | Common Stock (15700) | Direct |
Footnotes
F1: Grant of 1/2/13 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/14. Thereafter, the remaining shares subject to the option vest and become exerciable in 36 equal monthly installments, at the rate of 1,875 shares per year. The option is exercisable as to 0 on 1/1/13.
F2: Grant of 1/2/13 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/14. Thereafter, the remaining shares subject to the option vest and become exerciable in 36 equal monthly installments, at the rate of 3,925 shares per year. The option is exercisable as to 0 on 1/2/13.